CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Successor hearing aid to Junadevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03086018
NCT03086018N/ACompleted
CompareCT.gov

A Comparative, Controlled, Clinical Investigation and Quality Control of a New Hearing Aid in Comparison to the Currently Marketed Device

Bernafon AG·interventional·Posted Mar 22, 2017·Updated Nov 6, 2019

In Brief

A clinical study evaluating Successor hearing aid to Juna for Hearing Loss. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The aim of this study is to investigate the performance of the hearing aid under laboratory as well as everyday conditions. In addition, the performance data of the hearing aid are compared with a Bernafon hearing aid already available on the market. The hearing aids are adapted according to the user requirements. The data collected in the study is intended to show that the benefit of the hearing aid being examined is identical or better than the current CE-marked hearing aid. A further aim is to improve the adaptation of the hearing device in such a way that the benefit for people with hearing impairments can be increased.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHearing Loss
CountriesSwitzerland
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 22, 2017
Enrollment StartMar 13, 2017
Primary CompletionJun 28, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.3 years ago

Interventions

Successor hearing aid to Junadevice

The participants will all be experienced hearing instrument device users and will be switched from their current (control) devices to the new test device which succeeds the Juna device.